Skip to main content
. 2017 Sep 12;7:11306. doi: 10.1038/s41598-017-11751-7

Figure 1.

Figure 1

AZD4547 inhibits cell proliferation of ErbB2-overexpressing breast cancer cells in vitro. (a) MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. (b) MDA-MB-361, BT474, and SKBR3 cells were treated with AZD4547 (0, 1, 3, or 5 µM) for 12 days before cells were fixed and stained with crystal violet. The number of colonies that formed in each sample is presented in the graphs with representative images in the panels below. (c) MDA-MB-361 and BT474 cells were treated with AZD4547 (0, 3, or 5 µM) for 16 hours, then the cells were assessed for the percent of cells in G0/G1, S, and G2/M phase of the cell cycle using FACS analysis. The average percentages of cells in each phase are graphed. Values are presented as the mean ± S.E. (* P ≤ 0.05, ** P ≤ 0.01 as compared to the corresponding controls).